DRI buys Biogen's Benlysta royalties
This article was originally published in Scrip
Executive Summary
Biogen Idec has sold its royalty stream for lupus drug Benlysta (belimumab) to DRI Capital in exchange for larger payments over a shorter period which "allows us to accelerate payments that would otherwise have been spread over a longer time period as we prepare for multiple pivotal trial data readouts and potential product launches", said Biogen.